A citation-based method for searching scientific literature

Daria M Keller, Natasha Ahmed, Hamza Tariq, Malsha Walgamage, Thilini Walgamage, Azad Mohammed, Jadzia Tin-Tsen Chou, Marta Kałużna-Oleksy, Maciej Lesiak, Ewa Straburzyńska-Migaj. J Clin Med 2022
Times Cited: 4







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
128
50



Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
25


Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetologia 2018
649
25

Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
L Zanoli, A Granata, P Lentini, S Rastelli, P Fatuzzo, F Rapisarda, P Castellino. ScientificWorldJournal 2015
24
25


Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling.
Muthiah Vaduganathan, Vasanth Sathiyakumar, Avinainder Singh, Cian P McCarthy, Arman Qamar, James L Januzzi, Benjamin M Scirica, Javed Butler, Christopher P Cannon, Deepak L Bhatt. J Am Coll Cardiol 2018
80
25



Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.
David M Williams, Hannah Jones, Jeffrey W Stephens. Diabetes Metab Syndr Obes 2022
9
25

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
330
25

Mortality attributable to type 2 diabetes mellitus in Latin America and the Caribbean: a comparative risk assessment analysis.
Wilmer Cristobal Guzman-Vilca, Rodrigo M Carrillo-Larco. BMJ Open Diabetes Res Care 2022
1
100



Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
C D Sjöström, M Hashemi, J Sugg, A Ptaszynska, E Johnsson. Diabetes Obes Metab 2015
34
25

Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results.
Sean Kang, Subodh Verma, Ali Fatehi Hassanabad, Guoqi Teng, Darrell D Belke, Jameson A Dundas, David G Guzzardi, Daniyil A Svystonyuk, Simranjit S Pattar, Daniel S J Park,[...]. Can J Cardiol 2020
60
25

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Ralph A DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J Woerle, Uli C Broedl. Diabetes Care 2015
217
25


An update on the safety of SGLT2 inhibitors.
André J Scheen. Expert Opin Drug Saf 2019
75
25

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review.
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati. Int J Endocrinol Metab 2019
25
25

Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
40
25

Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.
Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, Woo Je Lee. PLoS One 2019
5
25

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Shang-Hung Chang, Ming-Jui Hung, Yuk-Ying Chan, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2021
8
25


Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day. J Clin Med 2019
26
25


Exploring New Drug Targets for Type 2 Diabetes: Success, Challenges and Opportunities.
Abhinav Kanwal, Navjot Kanwar, Sanjay Bharati, Prateek Srivastava, Shailendra P Singh, Salomon Amar. Biomedicines 2022
2
50

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
71
25

Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study.
Jakob S Knudsen, Signe S Knudsen, Adam Hulman, Daniel R Witte, Edward W Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T Sørensen, Reimar W Thomsen. Lancet Reg Health Eur 2022
4
25

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik. Cardiovasc Diabetol 2022
6
25

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022
11
25

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti. J Diabetes Res 2019
24
25

Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019.
Saeid Safiri, Nahid Karamzad, Jay S Kaufman, Arielle Wilder Bell, Seyed Aria Nejadghaderi, Mark J M Sullman, Maziar Moradi-Lakeh, Gary Collins, Ali-Asghar Kolahi. Front Endocrinol (Lausanne) 2022
15
25

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
25

Harms and benefits of sodium-glucose co-transporter 2 inhibitors.
Thomas Chesterman, Tilenka Rj Thynne. Aust Prescr 2020
5
25

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, David Z I Cherney. Kidney Int Rep 2022
5
25




Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan, Shoban B Varthya. J Family Med Prim Care 2022
3
33


Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Faiez Zannad. JAMA Cardiol 2017
219
25

An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.
Daniel S Hsia, Owen Grove, William T Cefalu. Curr Opin Endocrinol Diabetes Obes 2017
154
25

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami, Yuriko Hamaguchi, Chikayo Iwaya, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Nobuya Hamanoue, Ryoko Motonaga,[...]. Endocr J 2020
20
25


Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus.
Linmin Zhu, Qianyang Huang, Xiao Li, Bo Jin, Yun Ding, C James Chou, Kuo-Jung Su, Yani Zhang, Xingguo Chen, Kuo Yuan Hwa,[...]. Front Mol Biosci 2022
2
50

Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank.
Nicholas J Thomas, Samuel E Jones, Michael N Weedon, Beverley M Shields, Richard A Oram, Andrew T Hattersley. Lancet Diabetes Endocrinol 2018
201
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.